BPC-157 vs TB-500 — a research-context comparison

[DRAFT — titan-copy to expand]

BPC-157 and TB-500 are the two research peptides most often paired in vendor copy, frequently with vague language about "tissue support." From a research-context standpoint they are two quite different molecules — different in size, in origin, in research literature, and in the analytical-release specifications a credible vendor will publish.

This note compares them on the dimensions that actually matter for material verification, not on marketing claims.

Sequence and size

BPC-157 is a pentadecapeptide — 15 residues, monoisotopic mass approximately 1419.5 Da. TB-500 is a synthetic fragment of thymosin beta-4, marketed in research contexts as either the full 43-residue parent peptide or as a shorter active fragment. The 17-mer fragment LKKTETQ form is the most common, with a mass near 1924 Da. Read any vendor's TB-500 listing carefully — "TB-500" is not a single molecule, and the specification sheet should state which form is in the vial.

Stability profiles

Both peptides are typically shipped lyophilized. BPC-157 is regarded as relatively stable in solution under refrigeration; TB-500 is generally considered somewhat more sensitive to repeated freeze-thaw cycles. Vendors who do not publish reconstitution-stability data for either compound are publishing only the dry-lot specification, which is the easier half of the analytical record.

Documented purity specifications

A credible release for either compound includes greater than 98% HPLC purity at 220 nm with the chromatogram attached, a mass-spectrometric confirmation of the target mass for the named sequence, and a per-lot endotoxin value. The chromatogram is the discriminating field — two vials labeled identically can sit beside one another with very different peak profiles. The label is not the lot. The chromatogram is the lot.

Research literature

The literatures are largely non-overlapping. BPC-157 work has concentrated on gastrointestinal and connective-tissue models in rodents. TB-500 / thymosin-beta-4 work has concentrated on cardiac and corneal-tissue models, with a separate strand on actin-binding biochemistry. Neither corpus establishes human safety or efficacy, and neither compound is approved for human use in any jurisdiction.

References

Primary research for both compounds is indexed on PubMed:

• BPC-157 (pentadecapeptide) — PubMed research index
• Thymosin beta-4 (TB-500 parent) — PubMed research index

All citations link to the U.S. National Library of Medicine's PubMed database. Findings in animal or in-vitro models do not establish safety or efficacy in humans. Neither compound is approved for human use in any jurisdiction.